XML 87 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Intangible Assets
 12 Months Ended
Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible Assets
Intangible assets consisted of the following at December 31:
 
 
2012
 
2011
 
 
 
 
 
Product and license rights
 
$
7,352,308

 
$
6,518,798

Less: accumulated amortization
 
(520,385
)
 
(54,259
)
Total product and license rights
 
6,831,923

 
6,464,539

Patents
 
2,735,117

 
608,561

Less: accumulated amortization
 
(90,242
)
 
(50,389
)
Total patents
 
2,644,875

 
558,172

Trademarks
 
9,020

 
9,020

Less: accumulated amortization
 
(9,020
)
 
(8,667
)
Total trademarks
 
—

 
353

Total intangible assets
 
$
9,476,798

 
$
7,023,064


In 2011, the Company acquired the Kristalose trademark and FDA registration from Mylan Inc. The agreement requires the Company to make future quarterly payments over a seven-year period equal to a percentage of Kristalose net sales. The payments are being treated as consideration for the assets acquired, and are being capitalized and amortized over the remaining expected useful life of the acquired asset, generally 15 years.
During 2012, the Company recorded an additional $1.7 million in intangible assets for capitalized patent costs incurred in the protection of the Company's intellectual property.
Amortization expense related to product and license rights, trademarks and patents was $0.5 million, $0.7 million and $0.7 million in 2012, 2011 and 2010, and is expected to be approximately $0.7 million in each of the years 2013 through 2017.